BioNTech SE and Kite, a Gilead Company, have entered a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s pipeline of novel ...